Blood Transfusion Research Institute, Wuxi Red Cross Blood Center, 109 Xinmin Road, Wuxi, 214021, China.
Cell Biol Int. 2013 Sep;37(9):865-74. doi: 10.1002/cbin.10114. Epub 2013 May 7.
For patients lacking a human leucocyte antigen-matched donor, umbilical cord blood (UCB) is an ideal, alternative source of haematopoietic stem cells (HSCs) for transplantation purposes. UCB has many advantages over bone marrow or peripheral blood taken from volunteer donors. UCB is also an important source of other stem cells, including endothelial progenitors, mesenchymal stem cells, very small embryonic/epiblast-like (VSEL) stem cells, and unrestricted somatic stem cells, which are potentially suitable for regenerative medicine. However, a significant clinical problem is that the number of HSCs in one cord-blood unit is not enough for an adult transplantation. The development of new approaches including use of multiple donors, ex vivo expansion, increasing efficiency of homing and engraftment, retrieving more cells from the placenta and cord blood is of crucial importance for the delayed engraftment after UCB transplantation. In the future, UCB will emerge as a source of cells for cellular therapies associated with tissue repair and regeneration.
对于缺乏人类白细胞抗原匹配供体的患者，脐带血 (UCB) 是移植目的造血干细胞 (HSCs) 的理想替代来源。UCB 与来自志愿者供体的骨髓或外周血相比具有许多优势。UCB 也是其他干细胞的重要来源，包括内皮祖细胞、间充质干细胞、非常小的胚胎/外胚层样 (VSEL) 干细胞和无限制的体干细胞，这些干细胞可能适合再生医学。然而，一个显著的临床问题是，一个脐带血单位中的 HSCs 数量不足以用于成人移植。开发新方法包括使用多个供体、体外扩增、提高归巢和植入效率、从胎盘和脐带血中获取更多细胞对于 UCB 移植后延迟植入非常重要。未来，UCB 将成为与组织修复和再生相关的细胞治疗的细胞来源。
